Reshoring — the return of previously offshored production to a company's home country — and onshoring — the deliberate policy of incentivizing foreign firms to locate production domestically — have been among the most prominent economic policy narratives of the 2020s. In the United States, the CHIPS and Science Act, the Inflation Reduction Act, and the Infrastructure Investment and Jobs Act collectively committed over a trillion dollars to redirect manufacturing activity and supply chains back onto American soil. Similar industrial policy initiatives emerged in the European Union, Japan, South Korea, India, and the United Kingdom. The ideological consensus that had governed trade policy since the 1990s — comparative advantage, global supply chain optimization, market-led allocation — was revised, visibly and explicitly, in response to the accumulated evidence that unlimited globalization produced vulnerabilities that market forces alone could not address.
The proximate triggers for this revision are familiar: the COVID-19 pandemic exposed the fragility of globally dispersed supply chains for medical equipment, semiconductors, and pharmaceuticals; the war in Ukraine demonstrated the strategic vulnerability of energy import dependence; and the U.S.-China strategic competition created political pressure to reduce reliance on Chinese manufacturing across a wide range of dual-use technologies. These shocks did not create the reshoring and onshoring impulse ex nihilo — academic and policy debates about supply chain fragility and strategic industrial policy had been ongoing for decades — but they provided the political shock to overcome the institutional inertia that had kept globalization orthodoxy in place.
Law 5 — Revise — is the explicit logic of reshoring policy. The collective consensus about the optimal organization of global supply chains, built on decades of comparative advantage theory, cost minimization, and just-in-time inventory management, was found to be wrong in ways that inflicted severe, visible, collective harm. The revision was forced rather than chosen: it took the spectacle of hospitals unable to source N95 masks and automotive plants idled by semiconductor shortages to generate the political will to update the framework that had produced those vulnerabilities.
The economics of reshoring are, however, considerably more complicated than the policy narrative acknowledges. The cost differentials that drove original offshoring decisions — primarily labor costs — have not been eliminated by reshoring policy. American and European workers earn three to ten times the wages of their Chinese and Southeast Asian counterparts in comparable manufacturing roles. Reshoring policy compensates for this differential through a combination of automation investment (which reduces the labor cost component of manufactured goods), subsidy provision (which transfers the cost differential from the firm to the taxpayer), and regulatory mandate (which forces procurement choices that market prices would not support). Each of these mechanisms has distributional consequences and long-run fiscal implications that are only beginning to be assessed.
The semiconductor industry provides the clearest case study of reshoring's economics and politics. Intel, TSMC, and Samsung received tens of billions of dollars in CHIPS Act subsidies to build advanced semiconductor fabrication facilities in the United States. The facilities are being built, but the timeline, cost overruns, and workforce development challenges have all substantially exceeded initial projections. TSMC's Arizona fabs required the import of specialized construction workers from Taiwan because American construction trades lacked the specific skills needed; the ongoing workforce requirements will require substantial investment in semiconductor technician training programs that do not yet exist at adequate scale. The reshoring is proceeding, but at a cost and on a timeline that represent a significant revision of the initial optimistic projections.
The pharmaceutical industry presents a different pattern. Despite widespread political consensus that domestic pharmaceutical manufacturing capability needs to be rebuilt, progress has been slower than in semiconductors. The economics are less favorable: pharmaceutical manufacturing is highly automated, the labor cost differential between domestic and offshore production is smaller than in semiconductor fabrication, and the regulatory compliance requirements of FDA-grade pharmaceutical manufacturing are stringent regardless of location. The reshoring of API (active pharmaceutical ingredient) manufacturing, most of which is concentrated in India and China, has proven more difficult than the policy narrative anticipated, because the cost differential in that sector is driven less by labor and more by regulatory environment and supply chain ecosystem effects.
The distributional question — who benefits from reshoring — deserves more transparent accounting than it has received. The firms receiving reshoring subsidies are overwhelmingly large multinational corporations, not domestic small and medium enterprises; the employment created is often more capital-intensive and less labor-intensive than the displaced offshore employment it nominally replaces; and the geographic distribution of reshored facilities tends to favor already-prosperous metropolitan areas with existing infrastructure and talent pools rather than the deindustrialized communities most damaged by the original offshoring wave. Reshoring as economic policy for left-behind communities requires substantially more deliberate geographic targeting than current frameworks provide.
The international dimension adds further complexity. Trading partners whose exports are displaced by reshoring policy do not sit passively; they retaliate, escalate, or seek to negotiate bilateral arrangements that partially offset the reshoring effect. China's response to U.S. semiconductor restrictions has been accelerated domestic investment in competing capabilities — which, if successful, will erode the competitive advantage that the CHIPS Act is designed to create. The reshoring race is simultaneously a competitiveness policy and a geopolitical strategy, and the two objectives are not always aligned: the geopolitical objective of reducing China's semiconductor access can conflict with the competitiveness objective of maintaining American firms' technological leadership in open global markets.
The most honest collective revision acknowledges that reshoring and onshoring are not reversals of globalization but renegotiations of its terms — selective, strategic adjustments to the allocation of specific strategic industries and capabilities, embedded in a continuing global trading system. The political rhetoric of a wholesale return to domestic manufacturing is empirically unsustainable and, in aggregate welfare terms, undesirable. The practical question is which industries, which capabilities, and which supply chain nodes warrant domestic replication at above-market cost as insurance against strategic vulnerability — and that is a question that requires ongoing empirical revision as the threat environment, technology costs, and geopolitical landscape continue to evolve.